|
Edward C. Bradley, M.D., Chief Scientific Officer Edward Bradley, M.D. joins VioQuest from Berlex Laboratories, a wholly-owned U.S. subsidiary of Schering AG, (now Bayer-Schering Pharma) where he held several US and Corporate positions including Chief Medical Officer, Berlex Inc, and Head,Global Clinical Development, for one of Schering’s key global business sectors. He had direct responsibility for all aspects of clinical drug development from phase I through Phase IV, medical affairs, professional services, corporate product safety, biometrics, medical communications, and medical governance. Prior to his employment at Berlex Laboratories, Dr. Bradley was Executive Vice President, Worldwide Medical Science & Development at DuPont Pharmaceuticals from 1997 until its acquisition by Bristol-Myers in 2002. Prior to DuPont Pharmaceuticals, Dr. Bradley was Senior Vice President, Clinical Development, Sanofi Recherche (corporate) and Chief Medical Officer, Sanofi, Inc. (USA); Senior Vice President, Portfolio Management, Sanofi-Winthrop Research Division; Senior Vice President, Oncology in the Pharmaceutical Research Division of Sterling-Winthrop; and Executive Vice President of the Sterling Winthrop Immunoconjugates Division. Dr. Bradley is a Diplomat of the American Board of Internal Medicine and is certified by the Board of Medical Oncology. He received his M.D. degree from Harvard Medical School, where he also did his internship, residency, and was Chief Medical Resident. He served as a clinical associate at the National Cancer Institute, National Institutes of Health, has held appointments at Harvard Medical School, Stanford University, and the University of California, San Francisco. Served on the editorial board of scientific journals, and has numerous publications in peer reviewed medical journals in the areas of oncology and tumor immunology.
| 